Pharmacological manipulation of the Nrf2/Keap1 signalling pathway has the potential to reduce the rate of growth of primary pancreatic tumors, and render them more susceptible to attack by chemotherapeutic agents. Here, NFE2L2 is linked to pancreatic neoplasm.